ARCHIVES

NCI Advisors Criticize a Biomarker Study Touted as High Priority for NCI and FDA.

This article is from The Cancer Letter archive.

Vol. 33 No. 27 | July 13, 2007

Download PDF Visit The Full Archive

Related Articles

Enzalutamide Reduced Risk of Progression By 81 Percent in Metastatic Prostate Cancer

June 27, 2014

NCAB Committee Urged to Seek Surgical Oncology Certification

June 14, 1985

Targeting One Specific Protein Can Double PFS; Triple Overall Survival

May 27, 2011

Q & A With Shannon Brownlee: Task Force Independence at Stake In Debate over PSA Screening

October 6, 2011

Walter Curran Succeeds Brian Leyland-Jones As Director Of Emory’s Cancer Center

September 25, 2009

ORI finds Hopkins Coordinator Falsified Information On Grant

May 16, 1997